candy, page-18

"..Moving to bigger premises.."

This was covered in the August article in the Business Spectator'

TB diagnostic company Cellestis Ltd on August 25 reported a turnaround net profit of $2.256 million for the year ended June 30, 2008, up from a loss last year of $2.277 million, on revenue up 72% to $19.588 million.

Diluted EPS was 2.32c up from negative 2.35c last year. NTA backing per security was 15.6c compared to 13c last year.

The company said in the last year it has become both cash flow positive and profitable, reflecting the ongoing acceptance of QuantiFERON-TB Gold (QFT) in major markets. Landmark events during the year include the US In-Tube approval, the establishment of a Japanese office, the move to a larger and more effective service facility in the US and the publication of medical reports showing radically superior accuracy of QFT in predicting future TBTB